Search results
Products. Kyowa Kirin is a Japan-based Global Specialty Pharmaceutical Company, contributing to human health and well-being worldwide through innovative drug discovery and global commercialization, driven by state-of-the-art antibody technologies, in the core therapeutic areas of oncology, nephrology, central nervous system and immunology.
- English
English - Products - Kyowa Kirin
- Our Medicines
Our Medicines - Products - Kyowa Kirin
- Crysvita
Crysvita. ®. Crysvita ® is a recombinant fully human...
- Development
Development - Products - Kyowa Kirin
- Kyowa Kirin
The Kyowa Kirin Group is a Japanese pharma group that...
- English
By clicking the Send button, you authorize Kyowa Kirin, Inc., its affiliates, subsidiaries, and third-party agents to contact you by mail and/or email to provide information on products, programs, services, and disease-state information and/or utilize your information for market research or analytics.
The Kyowa Kirin Group is a Japanese pharma group that develops innovative specialty drugs, to raise the health and well-being of people around the world. Its flagship business Kyowa Kirin Co., Ltd. creates antibody-based drugs for cancer, kidney disease, and immune system diseases.
By clicking the Send button, you authorize Kyowa Kirin, Inc., its affiliates, subsidiaries, and third-party agents to contact you by mail and/or email to provide information on products, programs, services, and disease-state information and/or utilize your information for market research or analytics.
- 135 Route 202/206, Suite 6, Bedminster, 07921, New Jersey
- (908) 234-1096
Crysvita. ®. Crysvita ® is a recombinant fully human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23 (FGF23). By blocking excess FGF23 in patients, Crysvita ® is intended to increase phosphate reabsorption in the kidney and increase the production of vitamin D, which enhances intestinal absorption of ...
Kyowa Kirin International currently has two medicines in five indications, all across areas of rare disease: Poteligeo® treating cutaneous T-cell lymphoma (CTCL, a rare blood cancer) in two forms – mycosis fungoides and Sézary syndrome. Crysvita® in both adult and paediatric X-linked Hypophosphatemia (XLH, a rare bone metabolic disorder).
By clicking the Send button, you authorize Kyowa Kirin, Inc., its affiliates, subsidiaries, and third-party agents to contact you by mail and/or email to provide information on products, programs, services, and disease-state information and/or utilize your information for market research or analytics.
